Clinical Trial Update: A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating long-term safety of teriflunomide 14 mg daily in patients with a first clinical episode suggestive of multiple sclerosis; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Teriflunomide 14 mg (teriflunomide)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED